Advanced Cell Technology to Present at Stem Cell Meeting on the Mesa’s 2nd Annual Investor and Partnering Forum

  Advanced Cell Technology to Present at Stem Cell Meeting on the Mesa’s 2nd   Annual Investor and Partnering Forum  Business Wire  MARLBOROUGH, Mass. -- October 26, 2012  Advanced Cell Technology, Inc. (“ACT”; OTCBB: ACTC), a leader in the field of regenerative medicine, announced today that chairman and CEO Gary Rabin will present at the 2012 Stem Cell Meeting on the Mesa’s Investor and Partnering Forum, Oct. 29 and 30 in La Jolla, California.  In his presentation, Mr. Rabin will provide an overview of ACT’s ocular programs. The presentation will be webcast by theAlliance for Regenerative Medicinein the weeks following the conference.  The following are specific details regarding ACT’s presentation at the conference:  Stem Cell Meeting on the Mesa’s Second Annual Investor and Partnering Forum  Date:          Monday, Oct. 29                  Time:           1 p.m. PDT                  Location:       Sanford Consortium for Regenerative Medicine                 2880 Torrey Pines Scenic Drive, La Jolla, California 92037                   About the Stem Cell Meeting on the Mesa’s Investor and Partnering Forum  The Investor and Partnering Forum is being organized by the Sanford Consortium, CIRM and The Alliance for Regenerative Medicine (ARM) to facilitate translational research, promote engagement between the scientific and business communities and provide opportunities for business, academic research and investor participants to connect in one-on-one strategic partnering meetings. To learn more or to register for the 2011 Stem Cell Meeting on the Mesa Symposium and Investor & Partnering Forum, please visit www.stemcellmeetingonthemesa.com.  About Advanced Cell Technology, Inc.  Advanced Cell Technology, Inc., is a biotechnology company applying cellular technology in the field of regenerative medicine. For more information, visit www.advancedcell.com.  Forward-Looking Statements  Statements in this news release regarding future financial and operating results, future growth in research and development programs, potential applications of our technology, opportunities for the company and any other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Any statements that are not statements of historical fact (including statements containing the words “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates,” and similar expressions) should also be considered to be forward-looking statements. There are a number of important factors that could cause actual results or events to differ materially from those indicated by such forward-looking statements, including: limited operating history, need for future capital, risks inherent in the development and commercialization of potential products, protection of our intellectual property, and economic conditions generally. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in the company’s periodic reports, including the report on Form 10-K for the year ended December 31, 2011. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. Forward-looking statements are based on the beliefs, opinions, and expectations of the company’s management at the time they are made, and the company does not assume any obligation to update its forward-looking statements if those beliefs, opinions, expectations, or other circumstances should change. There can be no assurance that the Company’s clinical trials will be successful.  Contact:  Investors: CEOcast, Inc. James Young, 212-732-4300 or Press: ACT Corporate Communications Bill Douglass, 646-450-3615 or Russo Partners Martina Schwarzkopf, Ph.D., 212-845-4292  
Press spacebar to pause and continue. Press esc to stop.